Literature DB >> 16169381

Method and demonstration of direct confirmation of response to cardiac resynchronization therapy via preimplant temporary biventricular pacing and impedance cardiography.

J Rod Gimbel1.   

Abstract

Temporary resynchronization therapy pacing is feasible, and impedance cardiography (ICG) can provide evidence of hemodynamic benefit before permanent pacemaker implantation. During an electrophysiologic study performed before permanent device implantation, a guidewire was placed in a tributary of the coronary sinus to allow pacing of the left ventricle. Temporary pacing was implemented in various modalities, during which time ICG was used to document the hemodynamic consequences of atrial pacing, dual-chamber pacing, and biventricular pacing, with biventricular pacing being hemodynamically most favorable.

Mesh:

Year:  2005        PMID: 16169381     DOI: 10.1016/j.amjcard.2005.05.039

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  4 in total

Review 1.  Impedance cardiography: more questions than answers.

Authors:  David J Wang; Stephen S Gottlieb
Journal:  Curr Heart Fail Rep       Date:  2006-09

2.  Antazoline-insights into drug-induced electrocardiographic and hemodynamic effects: Results of the ELEPHANT II substudy.

Authors:  Roman Piotrowski; Joanna Giebułtowicz; Jakub Baran; Agnieszka Sikorska; Dagmara Gralak-Łachowska; Małgorzata Soszyńska; Piotr Wroczyński; Piotr Kułakowski
Journal:  Ann Noninvasive Electrocardiol       Date:  2017-02-25       Impact factor: 1.468

Review 3.  Impedance cardiography: more questions than answers.

Authors:  David J Wang; Stephen S Gottlieb
Journal:  Curr Cardiol Rep       Date:  2006-05       Impact factor: 2.931

4.  Temporary coronary sinus pacing to improve ventricular dyssynchrony with cardiogenic shock: A case report.

Authors:  Teressa Reanne Ju; Hsin Tseng; Hsin-Ti Lin; Alexander Lee Wang; Chi Chan Lee; Yi-Ching Lai
Journal:  World J Clin Cases       Date:  2021-07-16       Impact factor: 1.337

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.